PLOD2 gene expression in infrapatellar fat pad is correlated with fat mass in obese patients with end-stage knee osteoarthritis
- PMID: 38694906
- PMCID: PMC11061337
- DOI: 10.1016/j.ocarto.2024.100469
PLOD2 gene expression in infrapatellar fat pad is correlated with fat mass in obese patients with end-stage knee osteoarthritis
Abstract
Objective: To investigate associations between obesity-linked systemic factors and gene expression indicative for the inflammatory and fibrotic processes in the infrapatellar fat pad (IFP), in a population of obese patients with end-stage knee osteoarthritis (KOA).
Methods: We collected human IFPs from 48 patients with a mean body mass index (BMI) of 35.44 kg/m2 during total knee replacement procedures. These patients were part of a randomized controlled trial and met the criteria of having OA and a BMI of ≥30 kg/m2. Blood samples were collected to assess serum levels of glucose, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and leptin. Total body composition was measured using dual-energy X-ray absorptiometry. Gene expressions of IL6, TNFA, COL1A1, IL1B, ASMA, PLOD2 in the IFP were analyzed.
Results: Univariate analysis resulted in a positive correlation between BMI and procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 (PLOD2) expression (r2 = 0.13). In univariate analyses of obesity-linked systemic factors and PLOD2, significant correlations were found for lean mass (r2 = 0.20), fat mass (r2 = 0.20), serum cholesterol (r2 = 0.17), serum triglycerides (r2 = 0.19) and serum leptin (r2 = 0.10). A multiple linear regression model indicated fat mass to be a strong predictor of PLOD2 production in the IFP (r2 = 0.22, P = 0.003).
Conclusion: Our study demonstrates the positive association between fat mass and PLOD2 expression in the IFP of obese end-stage knee OA patients. This may indicate that within this patient population the fibrotic process in the IFP is influenced by systemic adipose tissue, next to local inflammatory processes.
Keywords: Fibrosis; Infrapatellar fat pad; Knee; Obesity; Osteoarthritis; PLOD2.
© 2024 The Author(s).
Conflict of interest statement
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11061337/bin/gr1.gif)
![formula image](https://cdn.statically.io/img/cdn.ncbi.nlm.nih.gov/corehtml/pmc/pmcents/pc-E00C.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11061337/bin/gr2.gif)
Similar articles
-
Lack of high BMI-related features in adipocytes and inflammatory cells in the infrapatellar fat pad (IFP).Arthritis Res Ther. 2017 Aug 11;19(1):186. doi: 10.1186/s13075-017-1395-9. Arthritis Res Ther. 2017. PMID: 28800775 Free PMC article.
-
The infrapatellar fat pad in knee osteoarthritis: an important source of interleukin-6 and its soluble receptor.Arthritis Rheum. 2009 Nov;60(11):3374-7. doi: 10.1002/art.24881. Arthritis Rheum. 2009. PMID: 19877065
-
Stimulation of fibrotic processes by the infrapatellar fat pad in cultured synoviocytes from patients with osteoarthritis: a possible role for prostaglandin f2α.Arthritis Rheum. 2013 Aug;65(8):2070-80. doi: 10.1002/art.37996. Arthritis Rheum. 2013. PMID: 23666869
-
The Corpus Adiposum Infrapatellare (Hoffa's Fat Pad)-The Role of the Infrapatellar Fat Pad in Osteoarthritis Pathogenesis.Biomedicines. 2022 May 5;10(5):1071. doi: 10.3390/biomedicines10051071. Biomedicines. 2022. PMID: 35625808 Free PMC article. Review.
-
Evaluation and treatment of disorders of the infrapatellar fat pad.Sports Med. 2012 Jan 1;42(1):51-67. doi: 10.2165/11595680-000000000-00000. Sports Med. 2012. PMID: 22149697 Review.
References
LinkOut - more resources
Full Text Sources
Miscellaneous